Rat 
vivo and leukocyte adherence inhibition reactions in vitro. Tumor specificity was demonstrated by employing as controls a chemically induced BALB/c fibrosarcoma, MCA-1511 (MCA, 3-methylcholanthrene), and its corresponding antiidiotypic antibody, 5.96. Lymphocytes from mice sensitized with antibody 21D9 or 5.96 specifically recognized antigens in extracts of BALB/c bladder carcinoma BTCC-1660 (BTCC, bladder transitional cell carcinoma) and sarcoma MCA-1511, respectively, as shown by leukocyte adherence inhibition reactivity. This reactivity was selectively abrogated by prior treatment of the sensitized cells with the appropriate antiidiotypic antibodies and complement. An antigen recognized in vitro by antibody 21D9-sensitized lymphocytes could be separated from BTCC-1660 extract by immunoabsorption with antibody 6.10 and elution with acidic buffer. Our findings indicate that the oncofetal antigen defined by antibody 6.10 is recognized by the immune system of syngeneic mice and suggest that antlidiotypic antibodies related to certain oncofetal antigens can be used to immunize against syngeneic tumors.
A variety of tumor-associated cell surface antigens has been detected in human neoplasms by mouse monoclonal antibodies. Many of these antigens are expressed strongly by tumors and certain embryonic cells and much more weakly by normal cells from the adult host and are, therefore, differentiation or oncofetal antigens (1, 2) . Other tumor-associated antigens have been detected by their ability to stimulate host cell-mediated immunity (CMI) in human cancer (3) (4) (5) (6) . Some of those antigens are also oncofetal, but their molecular nature and relationship to the antigens defined by monoclonal mouse antibodies are unclear. It is of great importance to know whether or not the antibody-defined, well-characterized antigens can induce an active immune response in the syngeneic host and, if so, what effects this response might have on neoplastic and normal cells.
Problems of this type may be best studied in an animal model. One such model was described by Taranger et al., who presented evidence for an in vivo response to antigens shared by bladder carcinomas, although no definitive conclusions could be drawn since the exact specificity of the implicated antigens was unknown (7) .
Rat monoclonal antibodies to antigens shared by mouse bladder carcinomas have been obtained recently (8, 9) . Two of these antibodies (9) have a degree of specificity for bladder tumors similar to that of the most specific monoclonal antibodies to human tumor antigens. We have started to investigate the relationships between one of these antibodies, 6.10 (9) , and the shared bladder tumor antigens implied by the work of Taranger et al. (7) . The findings reported here have implications for tumor immunotherapy and immunoprophylaxis using oncofetal antigens as targets.
MATERIALS AND METHODS
Animals. Brother-sister-mated BALB/c mice from the Fred Hutchinson Cancer Research Center colony were used for the induction and serial propagation of bladder carcinomas, for the immunization that led to the development of antibodies 21D9 and 43A10 (see below), and for delayed-type hypersensitivity (DTH) assays; all ofthis was done in Seattle. For logistic reasons, a second source of BALB/c mice had to be employed for the leukocyte adherence inhibition (LAI) tests, which were carried out in Brisbane. These mice, from the Central Animal Breeding House (University of Queensland), were also propagated by brother-sister mating; this allowed the progressive growth of a Seattle-derived bladder carcinoma, BTCC-1660 (BTCC, bladder transitional cell carcinoma), and a sarcoma, MCA-1511 (MCA, 3-methylcholanthrene) (see below), without signs of rejection.
Nude (nu/nu) mice from Charles River Breeding Laboratories were used for the propagation of rat hybridomas as ascites tumors.
Tumors. BTCC-1660 (9) was induced by MCA as described (10 
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Sprague-Dawley rat immunized by three weekly injections of irradiated BALB/c BTCC-1657 cells with NS-1 myeloma cells. The hybridoma was selected after initial screening with binding assays and immunohistology (9) . Hybridoma 6.10 was cloned twice by limiting dilution and propagated in nude mice as an ascites tumor. According to microzone electrophoresis (11), antibody 6.10 is monoclonal, and according to immunodiffusion tests, it is an IgG2a (9). It was purified by ammonium sulfate precipitation followed by DEAE chromatography for use in the present experiments. The specificity of antibody 6.10 was established by immunohistologic tests on frozen sections. The antibody was found to recognize an antigen expressed by all primary and transplanted bladder carcinomas tested, whether these were induced by chemical carcinogen MCA or 2-formylamino-4-(5-nitro-2-furyl)thiazole. No detectable binding to any other tumors was observed and only a few adult epithelia were faintly stained. The normal urinary bladder epithelium was negative but appreciable binding was found to several tissues of mouse embryo (9) .
Monoclonal antiidiotypic antibodies were obtained by injecting BALB/c mice subcutaneously with 100 Ag of purified antibody 6.10 in complete Freund's adjuvant followed by intraperitoneal injection of the same amount in incomplete Freund's adjuvant 5 days later. Mice were then injected with antibody 6.10 in saline for an additional two or three times at 5-day intervals. Spleen cells from the mice were harvested 3 days after the last injection and were hybridized with NS-1 cells. Hybridomas 21D9 and 43A10 were derived from two different fusions. Antibodies made by the hybridomas were initially screened for binding specifically to antibody 6.10 and not to purified normal rat serum IgG by using an ELISA (12, 13) . The hybridomas were cloned. They were propagated in pristane-primed BALB/c mice as ascites tumors. Antibodies 21D9 and 43A10 were found to be IgM by immunodiffusion.
We tested, as described (12) , to what extent antibody 6.10, compared to various rat monoclonal antibodies used as controls and also established by hybridization with NS-1 cells, could competitively inhibit the binding of antibodies 21D9 and 43A10 to antibody 6.10 on solid phase in an ELISA. The same assay was also performed with Nonidet P-40 extracts (12) from cultured cells of BTCC-1660 and sarcoma MCA-1511 (as a control) as inhibitors to establish whether the binding of antibodies 21D9 and 43A10 to antibody 6.10 could be competitively inhibited by bladder tumor antigen-containing extracts.
A syngeneic, monoclonal, antiidiotypic antibody, 5.96, was used as a control, since it can induce specific DTH to sarcoma MCA-1511 in BALB/c mice (Karen Nelson, personal communication) when tested as described for another antiidiotypic antibody-tumor combination (14) . It was induced by hybridizing spleen cells from MCA-1511 immune BALB/c mice with NS-1 cells.
Assay for DTH in Vivo. CMI to tumor antigens was first investigated in vivo by using an assay for DTH. The DTH was induced and measured in the same manner as described for an antiidiotypic antibody related to a chemically induced BALB/c sarcoma, MCA-1490 (14) ; the reactivity detected in the MCA-1490 system was found to be mediated by Thy-l+, Lyt-l+ cells and to have the histological characteristics of a DTH reaction (14) . In short, the mice (five per group) were each primed at various subcutaneous sites with 5-10 ,g of an antibody, and 5 days later 5 x 105 tumor cells were injected into one of their hind footpads. The footpads were measured 24 hr after injection of the tumor cells with an engineer's micrometer. The increase in swelling was calculated by comparison with the contralateral footpad that was not injected. All of the mice were individually earmarked and all measurements were done in a "blind" fashion.
Assay for LAI in Vitro. The LAI technique (4) was employed as an in vitro correlate of the DTH assay. This test measures immunoreactivity of Thy-1+, Lyt-l, L3T4' lymphocytes (4, 15) , which are stimulated by specific antigen to produce a lymphokine that decreases leukocyte adherence to glass.
As a primary source of effector cells, peritoneal cells (PC) were used from mice bearing transplanted tumors that were 5-10 mm in diameter. Mice injected one to three times with antibody 21D9, 43A10, or 5.96 (5 ,ug per injection) were also used to provide PC 5-10 days after the last injection. LAI reactivity was determined in hemocytometer chambers as described (4, 15) , using mixtures of PC and antigens in the form of tumor extracts (4, 15) or antiidiotypic antibodies at an optimal concentration as determined by prior titration. The extracts were prepared (4, 16) by homogenizing tumor tissue (1 vol) in phosphate-buffered saline at pH 7.2 (4 vol) and centrifuging the homogenate; the supernatants were stored in small volumes at -50'C. All determinations of % adherence of PC were done in a blind fashion on coded mixtures. The significance of differences between treatments was assessed by Student's t test, using means of 18-20 replicate determinations.
Immunoabsorption. Antibody 6.10 (1.5 mg) was coupled to 1.5 ml of swollen CNBr-Sepharose 4B gel (Pharmacia) as described by the manufacturers. Normal rat serum globulin on Sepharose gel was used as a control. For absorption of tumor extract, 1.0 ml of undiluted extract was mixed with 1.0 ml of coupled gel for 30 min at room temperature. The mixture was centrifuged briefly and the supernatant was reabsorbed with another 0.5-ml portion of gel. The gel portions were pooled, washed, and eluted with glycine buffer at pH 2.8 (three times with 0.5 ml). The pooled eluates were neutralized with sodium bicarbonate solution. Absorbed extracts and eluates were stored at -500C. Before use in LAI assays, their concentrations were adjusted to allow for dilution during absorption.
Treatment of PC with Antibodies and Complement. PC were pretreated with antiidiotypic antibodies and complement, before reacting in LAI assays, to test whether these antibodies could specifically inactivate antigen-reactive cells by binding to their receptors (17) . The antibodies (40-120 jig)
were incubated with PC (1 x 107 cells in 0.5 ml of medium) for 30 min at 370C. The cells were then washed and incubated with complement (1 ml of guinea pig serum diluted 1:6) for another 30 min at 370C. After the final wash, the treated PC were used as before in the assay. The effect of pretreatment on overall cell viability was negligible.
Experiments were also performed in which PC were pretreated with monoclonal antibodies to Thy-1.2 or L3T4 (provided by I. F. C. McKenzie and R. Scollay) and guinea pig complement as described (15) .
RESULTS
Antibodies 21D9 and 43A10 Are Specific for Idiotope(s) on Antibody 6.10. Antibody 6.10 was used to immunize mice to obtain monoclonal antibodies to idiotypic determinants on antibody 6.10. Two antibodies of desired specificity made by hybridomas 21D9 and 43A10 resulted from this approach. Table 1 shows that both antibodies bound to antibody 6.10 and that this binding was competitively inhibited by antibody 6 (Table 3 ). The same PC reacted in vitro with 43A10, as would be expected. T lymphocytes were required for the LAI reactivity. When PC from antibody 21D9-sensitized mice were incubated with complement but no antigen, the adherence was 67.1%. This adherence decreased to 55.6% when BTCC-1660 extract was also added. When anti-Thy-1.2 antibody was added to the mixture of PC, BTCC-1660 extract, and complement, the adherence increased to 66.6% (it was 62.5% in the absence of the BTCC-1660 extract)-that is, LAI reactivity was abolished. Pretreatment with antibody to L3T4 and complement, likewise, abrogated lymphocyte reactivity to BTCC-1660.
The Antigen Recognized by Antibody 21D9-Induced PC Is Absorbed from Tumor Extract by Antibody 6.10. When BTCC-1660 tumor extract was doubly absorbed with antibody 6.10 coupled to Sepharose gel, the residual absorbed extract no longer reacted in LAI with antibody 21D9-sensitized PC (Table 4) . However, it still reacted with BTCC-1660 tumor-bearer PC, indicating the existence of cells sensitized to antigen(s) in the tumor extract other than the one defined by antibody 6.10. Also shown in Table 4 are the results of testing the acid eluate from the above gel. This reacted with both types of PC and presumably contained the 6.10-related antigen in a purified form.
Use of Antibody 21D9 as a Specific Inhibitory Antibody for Idiotype-Positive Cells. To test further the specificity of the LAI reactivity induced by injecting mice with antibody 21D9, we examined whether this reactivity was lost after in vitro incubation of PC from the injected mice with antibody 21D9 and complement. This was done in an attempt to remove the Table 3. tSignificant LAI compared to control without antigen (P < 0.01).
tControl gel was coupled with normal rat serum globulin.
reactive cells that were expected to be idiotype-positive (17); incubation with antibody 5.96 was used as a control. As shown in Table 5 , reactivity to BTCC-1660 was abrogated by pretreatment with antibody 21D9, whereas antibody 5.96 had no effect. The reverse was found when PC from antibody 5.96-sensitized mice were pretreated with the same antibodies and tested against the MCA-1511 extract.
DISCUSSION
Previously we have generated a rat antibody, 6.10, to an oncofetal cell surface antigen of mouse bladder carcinomas. The antigen is a protein with a molecular mass of 175 kDa (9) . We now report that CMI can be induced against syngeneic mouse bladder carcinoma by monoclonal mouse antibodies to idiotopes on this rat antibody.
Two separate techniques were employed to demonstrate CMI-namely, DTH in vivo and LAI in vitro. Both provided evidence for tumor-specific CMI in antibody-injected mice. The demonstration of LAI reactions with well-characterized, tumor-related antigens, such as the reagents used here, should make this procedure more acceptable than in the past. Antibodies to lymphocyte surface markers identified LAIreactive cells from antibody 21D9-sensitized mice as belonging to the helper T-cell subset (Thy-l+, L3T4+), confirming previous results with tumor-bearing mice (15) .
The ability of cells from antibody 21D9-or 43A10-sensitized mice to react with BTCC-1660 tumor extract in vitro suggested that the relevant tumor antigen was present in that extract. This was confirmed by the immunoabsorption of antigenic activity from the extract by antitumor antibody 6.10 and its subsequent elution. The BALB/c mouse thus exhibits the ability to recognize and respond to an antigen shared by syngeneic bladder carcinomas, embryonic tissues, and (a few) adult cells of the host after sensitization with antibodies 21D9 and 43A10. The 175-kDa molecule was not the only antigen recognized by BTCC-1660 tumor-bearing mice and present in BTCC-1660 extract, since other antigens reactive with appropriate PC remained after absorption with antibody 6.10 (Table 4) . Antigens remaining in the absorbed extract might include the individually specific antigens commonly associated with chemically induced murine tumors (3) .
Much of our effort in this study went into investigating the specificity of the phenomena observed. Antiidiotypic antibodies 21D9 and 43A10 induced specific CMI in mice. The sensitized T cells recognized the tumor antigen in crude extracts and in partially purified eluates (in LAI) and in whole bladder tumor cells (in DTH). They recognized these antigens through receptors with specificity for a single idiotope since they could be specifically inhibited by the appropriate antiidiotypic antibody (Table 5) .
It has been reported that cancer patients (3-6, 18) and tumor-bearing animals (7, 19, 20) can mount CMI to shared tumor antigens, which may be oncofetal (21) . However, the relationship between the tumor-type specific antigens postulated to account for the cell-mediated responses detected in tumor-bearing hosts and those oncofetal antigens identified by using monoclonal antibodies was unclear prior to the present study. The molecular nature of the former antigens was unknown, and the latter antigens were commonly thought to be poorly immunogenic in the host since they are expressed in trace amounts in normal adult cells. The present findings bridge these two sets of observations by showing that (i) monoclonal antiidiotypic antibodies can be used to induce tumor-type specific CMI (Tables 2 and 3 ) and (ii) there is antitumor CMI in tumor-bearing mice to an antigen defined by a xenogeneic antibody (Table 4) .
Although idiotypic manipulations of tumor immunity have been reported (12, 14, 22, 23) , the present study is unique in that a defined oncofetal antigen in a syngeneic host was used as the target for the immune response rather than a tumorspecific transplantation antigen (10, 22, 23) or an oncofetal antigen introduced into a xenogeneic host (12) . Our system should be very useful for investigating how antiidiotypic antibodies can be used to manipulate the immune response to an oncofetal antigen in favor of the host. A key question is whether they can trigger cytotoxic responses to tumor cells (with a high density of antigen determinants) but spare normal cells (with fewer of the same determinants). An affirmative answer would have implications for tumor therapy and perhaps even for tumor prevention.
